Keeps Biopharma Inc.

KOSDAQ:A256940 Stock Report

Market Cap: ₩126.9b

Keeps Biopharma Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Young Kim Ha

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Analysis Article • Jan 06

Is Keeps Biopharma (KOSDAQ:256940) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Dec 01

Keeps Biopharma Inc.'s (KOSDAQ:256940) Shares Not Telling The Full Story

There wouldn't be many who think Keeps Biopharma Inc.'s ( KOSDAQ:256940 ) price-to-sales (or "P/S") ratio of 1.3x is...
Analysis Article • Sep 06

Is Keeps Biopharma (KOSDAQ:256940) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Aug 01

Not Many Are Piling Into Keeps Biopharma Inc. (KOSDAQ:256940) Stock Yet As It Plummets 27%

Keeps Biopharma Inc. ( KOSDAQ:256940 ) shares have retraced a considerable 27% in the last month, reversing a fair...
Analysis Article • Jun 17

Market Participants Recognise Keeps Biopharma Inc.'s (KOSDAQ:256940) Revenues Pushing Shares 43% Higher

Keeps Biopharma Inc. ( KOSDAQ:256940 ) shares have continued their recent momentum with a 43% gain in the last month...
Analysis Article • May 15

Is Keeps Biopharma (KOSDAQ:256940) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Apr 18

Further Upside For Keeps Biopharma Inc. (KOSDAQ:256940) Shares Could Introduce Price Risks After 33% Bounce

Keeps Biopharma Inc. ( KOSDAQ:256940 ) shares have continued their recent momentum with a 33% gain in the last month...
Analysis Article • Feb 06

A Piece Of The Puzzle Missing From KPS Corporation's (KOSDAQ:256940) 33% Share Price Climb

The KPS Corporation ( KOSDAQ:256940 ) share price has done very well over the last month, posting an excellent gain of...
Analysis Article • Jan 13

KPS (KOSDAQ:256940) Takes On Some Risk With Its Use Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Dec 06

A Piece Of The Puzzle Missing From KPS Corporation's (KOSDAQ:256940) Share Price

There wouldn't be many who think KPS Corporation's ( KOSDAQ:256940 ) price-to-sales (or "P/S") ratio of 0.7x is worth a...
Analysis Article • Mar 31

KPS (KOSDAQ:256940) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Despite posting some strong earnings, the market for KPS Corporation's ( KOSDAQ:256940 ) stock hasn't moved much. We...
Analysis Article • Feb 26

Sentiment Still Eluding KPS Corporation (KOSDAQ:256940)

With a median price-to-sales (or "P/S") ratio of close to 1.8x in the Semiconductor industry in Korea, you could be...

CEO

Young Kim Ha

no data
Tenure

Young Kim Ha is Chief Executive Officer of Keeps Biopharma Inc. (formerly known as KPS Corporation).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/10 16:29
End of Day Share Price 2026/08/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Keeps Biopharma Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
YoungSik YoonShinhan Investment Corp.
Sun-Jae HeoSK Securities Co., Ltd.